Company intelligence / Profile preview

Callidus Biopharma

Doylestown, Pennsylvania, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Lead Pompe ERT (recombinant acid-alpha glucosidase) demonstrated superior cellular uptake and activity in preclinical studies compared to the market standard (Lumizyme®). The platform had promising preclinical results for shortening infusion times, reducing immunogenicity, and boosting efficacy for LSDs.

Therapeutic areas: Metabolic DisordersRare Diseases
Modalities: Enzyme replacement therapyRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Callidus Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Callidus Biopharma.

Explore the full profile